PMC:7228307 / 574-1167 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"20","span":{"begin":366,"end":370},"obj":"Gene"},{"id":"21","span":{"begin":9,"end":13},"obj":"Gene"},{"id":"26","span":{"begin":106,"end":112},"obj":"Disease"},{"id":"27","span":{"begin":553,"end":560},"obj":"Disease"},{"id":"28","span":{"begin":562,"end":583},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Gene:2213"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:D009369"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D009369"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"MESH:D007249"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":113,"end":118},"obj":"Body_part"},{"id":"T6","span":{"begin":128,"end":136},"obj":"Body_part"},{"id":"T7","span":{"begin":271,"end":280},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":106,"end":112},"obj":"Disease"},{"id":"T3","span":{"begin":562,"end":583},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":9,"end":11},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T10","span":{"begin":113,"end":118},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T11","span":{"begin":323,"end":326},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T12","span":{"begin":341,"end":342},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":366,"end":368},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":23,"end":31},"obj":"Chemical"},{"id":"T5","span":{"begin":248,"end":262},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_33839"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T5","span":{"begin":113,"end":118},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T6","span":{"begin":575,"end":583},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T1","span":{"begin":248,"end":262},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33839"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"20","span":{"begin":366,"end":370},"obj":"Gene"},{"id":"21","span":{"begin":9,"end":13},"obj":"Gene"},{"id":"26","span":{"begin":106,"end":112},"obj":"Disease"},{"id":"27","span":{"begin":553,"end":560},"obj":"Disease"},{"id":"28","span":{"begin":562,"end":583},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"pubann:denotes","subj":"20","obj":"Gene:2213"},{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"},{"id":"A26","pred":"pubann:denotes","subj":"26","obj":"MESH:D009369"},{"id":"A27","pred":"pubann:denotes","subj":"27","obj":"MESH:D009369"},{"id":"A28","pred":"pubann:denotes","subj":"28","obj":"MESH:D007249"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T8","span":{"begin":60,"end":294},"obj":"Sentence"},{"id":"T9","span":{"begin":295,"end":511},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T5","span":{"begin":113,"end":118},"obj":"Body_part"},{"id":"T6","span":{"begin":128,"end":136},"obj":"Body_part"},{"id":"T7","span":{"begin":271,"end":280},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T1","span":{"begin":158,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":106,"end":112},"obj":"Disease"},{"id":"T2","span":{"begin":562,"end":583},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T1","span":{"begin":106,"end":112},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T1","span":{"begin":158,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":158,"end":170},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":60,"end":294},"obj":"Sentence"},{"id":"T9","span":{"begin":295,"end":511},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":106,"end":112},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"e potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emergi"}